Jiangsu Recbio Technology Co., Ltd.
江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2179)

VOLUNTARY ANNOUNCEMENT

ACCEPTANCE OF CLINICAL TRIAL APPLICATION FOR THE COMPANY'S NOVEL ADJUVANTED RECOMBINANT SHINGLES VACCINE REC610 IN CHINA AND OVERSEAS CLINICAL TRIAL PROGRESS

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on voluntary basis. Reference is made to the Company's voluntary announcement dated February 13, 2023 in relation to the completion of the first batch of subject enrollment for the Phase I clinical trial of the Company's novel adjuvanted recombinant shingles vaccine, REC610 ("**REC610**") in the Philippines.

The board of directors of the Company (the "**Board**") is pleased to announce that the Group has recently received the notice of acceptance (acceptance number: CXSL2300518) issued by National Medical Products Administration ("**NMPA**"), pursuant to which the clinical trial application for its self-developed novel adjuvanted recombinant shingles vaccine REC610 has been accepted. Within 60 days from the date of acceptance, the Company may carry out clinical trials in accordance with the submitted plan if no negative or doubtful comments are received from the Center for Drug Evaluation of NMPA.

The Company proposes to adopt a randomized, double-blind, Shingrix® parallel controlled phase I clinical trial in 180 healthy adult subjects aged 40 and above in Mainland China to evaluate the safety, tolerability of REC610 and have a preliminary assessment of its immunogenicity.

Shingles is a common viral infectious disease that seriously affects the quality of life of patients, especially elderly patients. It is estimated that more than 1.5 million new cases of shingles occur each year in people aged 50 and over in China. In recent years, with the accelerated pace of life, the incidence of shingles has gradually become younger. REC610 is equipped with a novel adjuvant BFA01 independently developed by the Company, which can promote the production of high levels of VZV glycoprotein E (gE)-specific CD4+ T cells and antibody. REC610 is intended to prevent shingles in adults aged 40 and above. Preclinical studies have shown that REC610 has favorable immunogenicity and can induce high levels of gE antigen-specific CD4+T cell responses and IgG antibody, and its immune response is non-inferior to the controlled vaccine Shingrix®.

Previously, the Company commenced the first-in-human GSK Shingrix® active controlled clinical trial of REC610 in the Philippines in February 2023. Currently, the clinical trial is being executed smoothly. All subjects have completed 30 days of follow-up studies after two doses of the vaccination, with favorable safety and tolerability profile.

Shareholders and potential investors should note that the Group may not develop or market REC610 successfully and should exercise caution when dealing in the securities of the Company.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Dr. Liu Yong
Chairman

Jiangsu Province, the PRC, July 26, 2023

As at the date of this announcement, the Board comprises Dr. LIU Yong as the chairman of the Board and an executive Director, Dr. CHEN Jianping, Mr. LI Bu and Ms. CHEN Qingqing as executive Directors, Dr. HONG Kunxue, Dr. ZHOU Hongbin, Mr. ZHANG Jiaxin and Mr. HU Houwei as non-executive Directors, and Mr. LIANG Guodong, Dr. XIA Lijun, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive Directors.